← Oncology Approval Tracker

FDA DECISION ·

Posfrea

palonosetron · Avyxa Holdings

FDA approvalNew or expanded indicationChemotherapy-induced nausea and vomiting
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For children from age 1 month to under age 17 to prevent acute nausea and vomiting associated with initial or repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The approval extends this palonosetron injection’s antiemetic indication to young children receiving cancer chemotherapy.

What research teams should watch

Use age- and weight-specific orders and administer at the appropriate time before the chemotherapy regimen.

PRIMARY RECORDS

Sources